Table 5.
Prevalence of males and females per year divided by age groups and relative p-values in the (a) pre-pandemic and (b) pandemic eras.
| (a) | 2015 | 2016 | 2017 | 2018 | 2019 | 2015–2019 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age/Gender | M | F | M | F | M | F | M | F | M | F | M | F |
| 0–10 | 0% | 0.1% | 0.1% | 0.4% | 0.2% | 0.3% | 0.5% | 0.1% | 0.2% | 0.3% | 0.2% | 0.2% |
| 11–20 | 0.7% | 0.6% | 1.0% | 0.4% | 1.8% | 0.6% | 1.4% | 0.8% | 0.8% | 0.3% | 1.2% | 0.5% |
| 21–30 | 1.8% | 0.6% | 1.0% | 1.6% | 1.0% | 1.8% | 1.6% | 1.3% | 1.7% | 0.8% | 1.4% | 1.2% |
| 31–40 | 2.7% | 2.0% | 2.4% | 2.0% | 3.2% | 2.1% | 2.2% | 2.8% | 2.6% | 1.2% | 2.6% | 2.0% |
| 41–50 | 8.4% | 8.5% | 7.6% | 7.5% | 8.1% | 8.1% | 6.9% | 7.0% | 4.4% | 5.0% | 7.0% | 7.1% |
| 51–60 | 22.3% | 26.3% | 18.4% | 18.6% | 21.1% | 23.1% | 20.4% | 22.0% | 17.7% | 28.3% | 19.8% | 22.0% |
| 61–70 | 26.8% | 26.2% | 30.2% | 29.0% | 29.5% | 26.0% | 31.0% | 28.0% | 32.4% | 28.8% | 30.1% | 27.6% |
| 71–80 | 27.0% | 22.3% | 29.2% | 26.4% | 25% | 26.5% | 26.5% | 25.8% | 29.6% | 30.0% | 27.6% | 26.3% |
| 81–90 | 9.8% | 12.7% | 9.7% | 13.0% | 9.6% | 10.9% | 9.3% | 10.8% | 10.2% | 12.2% | 9.7% | 11.9% |
| 90–95 | 0.5% | 0.6% | 0.4% | 1.0% | 0.6% | 0.6% | 0.3% | 1.2% | 0.4% | 1.2% | 0.4% | 1.0% |
| Total | 56.5% | 43.5% | 61.4% | 38.6% | 58.8% | 41.2% | 56.5% | 43.5% | 59.8% | 40.2% | 58.7% | 41.3% |
| Total positive | 1916 | 2202 | 2097 | 2248 | 2464 | 10,927 | ||||||
| p-value | 0.022 | 0.045 | 0.059 | 0.087 | 0.002 | <0.001 | ||||||
| (b) | 2020 | 2021 | 2022 | 2023 | 2020–2023 | |||||||
| Age/Gender | M | F | M | F | M | F | M | F | M | F | ||
| 0–10 | 0% | 0% | 0% | 0% | 0.2% | 0.3% | 0.1% | 0% | 0.1% | 0.1% | ||
| 11–20 | 0.2% | 0.8% | 0.1% | 0.4% | 0.2% | 1.0% | 0.3% | 0.5% | 0.2% | 0.7% | ||
| 21–30 | 1.5% | 1.5% | 1.5% | 0.9% | 1.5% | 1.4% | 1.5% | 0.5% | 1.5% | 1.0% | ||
| 31–40 | 2.3% | 1.5% | 2.8% | 1.9% | 1.4% | 2.4% | 1.7% | 1.7% | 2.0% | 1.9% | ||
| 41–50 | 6.3% | 5.1% | 4.7% | 4.6% | 3.4% | 4.8% | 3.2% | 4.4% | 4.3% | 4.7% | ||
| 51–60 | 20.0% | 17.8% | 18.6% | 18.7% | 16.7% | 16.0% | 16.3% | 15.2% | 17.7% | 16.7% | ||
| 61–70 | 29.6% | 28.2% | 31.3% | 25.9% | 33.7% | 27.0% | 30.7% | 27.4% | 31.4% | 27.1% | ||
| 71–80 | 28.4% | 30.3% | 30.5% | 30.4% | 28.6% | 26.0% | 32.3% | 28.3% | 30.1% | 28.5% | ||
| 81–90 | 11.4% | 12.8% | 9.8% | 14.7% | 12.8% | 18.1% | 12.9% | 19.1% | 11.9% | 16.6% | ||
| 90–95 | 0.3% | 1.9% | 0.7% | 2.5% | 1.5% | 3.0% | 0.9% | 2.9% | 0.9% | 2.6% | ||
| Total | 60.2% | 39.8% | 57.3% | 42.7% | 57.4% | 42.6% | 56.7% | 43.3% | 57.8% | 42.2% | ||
| Total positive | 1958 | 2172 | 2676 | 2880 | 9686 | |||||||
| p-value | 0.006 | <0.001 | <0.001 | <0.001 | <0.001 | |||||||